| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000006922 |
| Receipt No. | R000008169 |
| Scientific Title | Application test of a skin care medicine (cleansing agent) in patients with skin diseases such as atopic dermatitis and asteatotic dermatitis. |
| Date of disclosure of the study information | 2011/12/23 |
| Last modified on | 2019/03/31 (Ver. 12) |
| Basic information | ||
| Public title | Application test of a skin care medicine (cleansing agent) in patients with skin diseases such as atopic dermatitis and asteatotic dermatitis. | |
| Acronym | Application test of a skin care medicine (cleansing agent) in patients with skin diseases such as atopic dermatitis and asteatotic dermatitis. | |
| Scientific Title | Application test of a skin care medicine (cleansing agent) in patients with skin diseases such as atopic dermatitis and asteatotic dermatitis. | |
| Scientific Title:Acronym | Application test of a skin care medicine (cleansing agent) in patients with skin diseases such as atopic dermatitis and asteatotic dermatitis. | |
| Region |
|
|
| Condition | ||
| Condition | The test participants are patients with a condition, such as atopic dermatitis or asteatotic dermatitis, who presented with symptoms of inflammation and xerosis. | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To offer a cleansing agent that can be used at ease as a skin care medicine in daily life and the appropriate directions for the patient with dermatosis with skin dryness and an inflammation such as atopic dermatitis and asteatotic dermatitis. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | The severity of symptoms (erythema, papule, desquamation, xerosis, etc.) of the subject must not worsen, and the morphology and area of the stratum corneum (indicates the degree of cornification of the epidermal cells) |
| Key secondary outcomes | Skin measurements were performed by using measuring devices and analyzing the horny cell layer by using tape-stripping method.
Moisture content of the epidermal horny cell layer, amount of moisture loss through the skin, cytokines in the horny cell layer |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | After 4 weeks of conditioning, for normal personal use, substitute the cleansing agent with the product of this study. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Progression of the underlying disease was slow; therefore, the attending physician considered the product to be useful in maintaining and improving skin condition.
2.Patient who can be medically examined at 4 and 8 weeks (a deviation of 1 week before or after is allowed) after the start of the study 3.Patient from whom written consent (consent from a legal guardian in case of minors) can be obtained. Further information about age and sex need not be asked. |
|||
| Key exclusion criteria | 1.irritation or an allergic skin reaction because of the use of the product.
2.Patients with severe skin rashes such as contagious impetigo or Kaposi varicelliform eruption in the area where the product was used 3.Patients who cannot be medically examined at 4 and 8 weeks (as a general rule) after the start of the study 4.Patient whose participation in the study is deemed inappropriate by the attending physician |
|||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Kyusyu University | ||||||
| Division name | Department of Dermatology, Graduate School of Medical Sciences | ||||||
| Zip code | 812-0054 | ||||||
| Address | 3-1-1 Maidashi Higashi-ku Fukuoka 812-8582 JAPAN | ||||||
| TEL | 092-642-5596 | ||||||
| takeuchs@dermatol.med.kyushu-u.ac.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | Kyusyu University Hospital | ||||||
| Division name | Dermatology | ||||||
| Zip code | 812-0054 | ||||||
| Address | 3-1-1 Maidashi Higashi-ku Fukuoka 812-8582 JAPAN | ||||||
| TEL | 092-642-5596 | ||||||
| Homepage URL | http://www.kyudai-derm.org/part/treat/recent.html | ||||||
| takeuchs@dermatol.med.kyushu-u.ac.jp | |||||||
| Sponsor | |
| Institute | Kyusyu University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Tokiwa Pharmaceutical Co.,Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | JAPAN |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Kyusyu University Hospital Certified Review Board |
| Address | 3-1-1 Maidashi Higashi-ku Fukuoka 812-8582 JAPAN |
| Tel | 092-642-5774 |
| bynintei@jimu.kyushu-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 九州大学病院(福岡県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 20 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008169 |